



# BRACHYTHERAPY

## GEC-ESTRO Urology

The **UROGEC continues** to work in close collaboration with Brachyqs holding joint meetings at which common areas of work are discussed. In the absence of face to face meetings during the Covid crisis virtual meetings have been a successful alternative

### Focal prostate brachytherapy RCT

This trial protocol was developed by UROGEC now named the POWER study. With funding from the Dutch Cancer Society, together with support from Elekta and the German Cancer Society the trial was launched in 2018 but accrual has been slow mainly because approvals across different European countries each with different regulations and requirements have had to be negotiated by local investigators. The Covid-19 crisis has also halted trial accrual since March 2020. Following a review by the main funder ongoing support has been agreed with clear timelines and accrual targets. A protocol amendment is pending and once approval is given we hope to restart patient entry in 2021. The target accrual remains 220 patients.

### Salvage brachytherapy:

A central database to collect a cohort of salvage brachytherapy patients with outcomes is being set up by Piotr Wojcieszek in Warsaw.

### Bladder tolerances:

This work has continued with a detailed analysis of bladder base and urethral dosimetry in relation to stricture formation. A clear relation between dwell times close to the urethra and stricture has been identified. This work was accepted for a poster presentation at ESTRO 2020.

### ESTRO-ACROP Prostate Guidelines:

These are now close to completion and following ratification in the UroGEC and Brachyqs groups will be submitted for publication.



Chair: Peter Hoskin